HCLTech currently trades at a 1-year forward multiple of 23.7x, representing a 35%+ premium to its 10-year historical average. (Photo: HCLTech) Systematix remains cautiously optimistic about HCLTech's sustaining growth in H2, supported by a healthy deal pipeline and reasonable visibility on revenue, while monitoring profitability trends.

To continue reading this story You must be an existing Premium User Already a Premium User? Sign In

See Full Page